Dr Ross Maxwell
Senior Lecturer in Oncology Magnetic Resonance Research
- Email: ross.maxwell@ncl.ac.uk
- Telephone: 0191 256 3691 x 21107
- Fax: 0191 256 3692
- Address: Northern Institute for Cancer Research
Paul O'Gorman Building
Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
Research Interests
Magnetic Resonance Imaging and Spectroscopy
Positron Emission Tomography
Selected Publications
- Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ. Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. Journal of Clinical Oncology 2003, 21(15), 2831-2842.
- Nielsen FU; Daugaard P; Bentzen L; Stodkilde-Jorgensen H; Overgaard J; Horsman MR; Maxwell RJ. Effect of Changing Tumor Oxygenation on Glycolytic Metabolism in a Murine C3H Mammary Carcinoma Assessed by in Vivo Nuclear Magnetic Resonance Spectroscopy. Cancer Research 2001, 61(13), 5318-5325.
- Maxwell RJ; Prise VE; Vojnovic B; Rustin GJ; Lodge MA; Tozer GM; Wilson J. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine 2002, 15(2), 89-98.
- Seddon BM; Maxwell RJ ; Grimshaw R; Raynaud F; Tozer GM; Workman P; Honess DJ. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research 2002, 8(7), 2323-2335.
- Breidahl T; Nielsen FU; Stodkilde-Jorgensen H; Maxwell RJ; Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: acomparative assessment using MRI and MRS. Acta Oncologica 2006, 45(3), 306-316.
Qualifications
BPharm
PhD
Memberships
British Association of Cancer Research
International Society of Magnetic Resonance in Medicine
